Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease

Journal of Infectious Diseases

Volumn 196, Issue 2, 2007, Pages 266-270

  Erard, Veronique ^a   Wald, Anna ^a   Corey, Lawrence ^a   Leisenring, Wendy M ^a   Boeckh, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID; VALACICLOVIR; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DRUG DOSE INCREASE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS CULTURE; VIRUS INFECTION;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMANS; INFANT; LONGITUDINAL STUDIES; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMPLEXVIRUS;

EID: 34447278536     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518938     Document Type: Article

References (13)

1. Vartian CV. Acyclovir and overuse of antibiotics. Ann Intern Med 1984; 100:463.
2. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000; 181:2055-8.
3. Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 2002; 99:1085-8.
4. Darville JM, Ley BE, Roome AP, Foot AB. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 1998; 22:587-9.
5. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31:927-35.
6. Kalbfleisch J, Prenctice R. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
7. Grambsch PM, Therneau TM. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika 1994; 81:515-26.
8. Leung HM, Kupper LL. Comparisons of confidence intervals for attributable risk. Biometrics 1981; 37:293-302.
9. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16:114-28.
10. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 2006; 107:1800-5.
11. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380-9.
12. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99:3050-6.
13. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343:749-53.